1-phenyl-2-palmitoylamino-3-morpholino-1-propanol has been researched along with paclitaxel in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cabot, MC; Giuliano, AE; Gouazé, V; Liu, YY; Prickett, CS; Yu, JY | 1 |
1 other study(ies) available for 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol and paclitaxel
Article | Year |
---|---|
Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gangliosides; Glucosyltransferases; Humans; Morpholines; Oligonucleotides, Antisense; Paclitaxel; Sphingolipids; Transfection; Vinblastine | 2005 |